MX2012004134A - Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico. - Google Patents
Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico.Info
- Publication number
- MX2012004134A MX2012004134A MX2012004134A MX2012004134A MX2012004134A MX 2012004134 A MX2012004134 A MX 2012004134A MX 2012004134 A MX2012004134 A MX 2012004134A MX 2012004134 A MX2012004134 A MX 2012004134A MX 2012004134 A MX2012004134 A MX 2012004134A
- Authority
- MX
- Mexico
- Prior art keywords
- beta
- combination therapy
- receptor agonist
- adrenergic receptor
- antimuscarinic agent
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 239000003149 muscarinic antagonist Substances 0.000 title abstract 2
- 229940126158 β3 adrenergic receptor agonist Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000020629 overactive bladder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24938609P | 2009-10-07 | 2009-10-07 | |
| PCT/US2010/050328 WO2011043942A1 (en) | 2009-10-07 | 2010-09-27 | Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012004134A true MX2012004134A (es) | 2012-05-08 |
Family
ID=43857059
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012004134A MX2012004134A (es) | 2009-10-07 | 2010-09-27 | Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120202819A1 (https=) |
| EP (1) | EP2485595A4 (https=) |
| JP (1) | JP5738871B2 (https=) |
| KR (1) | KR20120093859A (https=) |
| CN (1) | CN102638987A (https=) |
| AU (1) | AU2010303811B2 (https=) |
| BR (1) | BR112012007829A2 (https=) |
| CA (1) | CA2774992A1 (https=) |
| IL (1) | IL218756A0 (https=) |
| IN (1) | IN2012DN02782A (https=) |
| MX (1) | MX2012004134A (https=) |
| NZ (1) | NZ599233A (https=) |
| RU (1) | RU2012118668A (https=) |
| WO (1) | WO2011043942A1 (https=) |
| ZA (1) | ZA201202520B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| AU2011285928B9 (en) * | 2010-08-03 | 2018-08-02 | B3Ar Therapeutics, Inc. | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| US8940763B2 (en) * | 2011-05-10 | 2015-01-27 | Theravida, Inc. | Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder |
| ES2584427T3 (es) | 2011-10-27 | 2016-09-27 | Merck Sharp & Dohme Corp. | Proceso para la preparación de agonistas beta 3 y productos intermedios |
| WO2013062881A1 (en) * | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Process for making beta 3 agonists and intermediates |
| TW201338772A (zh) * | 2012-02-09 | 2013-10-01 | Altherx Inc | 藥學組合物 |
| RS59402B1 (sr) * | 2013-03-15 | 2019-11-29 | Merck Sharp & Dohme | Postupak za pripremu beta 3 agonista i međuproizvoda |
| CN105579057A (zh) * | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| JP2017535567A (ja) | 2014-11-20 | 2017-11-30 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | アルファ−アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物 |
| HK1245117A1 (zh) | 2014-12-03 | 2018-08-24 | Velicept Therapeutics, Inc. | 使用调节释放索拉贝隆用於下尿路症状的组合物和方法 |
| US20180360845A1 (en) * | 2015-07-20 | 2018-12-20 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| ES2967863T3 (es) | 2015-10-23 | 2024-05-06 | B3Ar Therapeutics Inc | Ion dipolar de solabegron y usos del mismo |
| WO2018039159A1 (en) * | 2016-08-22 | 2018-03-01 | Chase Pharmaceuticals Corporation | Muscarinic m2-antagonist combination |
| EP3634420A1 (en) | 2017-06-06 | 2020-04-15 | Urovant Sciences GmbH | Use of vibegron to treat overactive bladder |
| JP7670461B2 (ja) * | 2017-06-06 | 2025-04-30 | ウロバント サイエンシズ ゲゼルシャフト ミット ベシュレンクター ハフトゥング | 過活動膀胱の治療のためのビベグロンの投薬 |
| KR102735800B1 (ko) * | 2017-12-21 | 2024-11-28 | 교린 세이야쿠 가부시키가이샤 | 야간빈뇨 치료제 |
| SG11202103662VA (en) | 2018-12-05 | 2021-06-29 | Urovant Sciences Gmbh | Vibegron for the treatment of overactive bladder symptoms |
| CN115850286B (zh) * | 2022-12-05 | 2023-08-22 | 奥锐特药业(天津)有限公司 | 一种维贝格龙中间体及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2789076B1 (fr) * | 1999-02-02 | 2001-03-02 | Synthelabo | Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique |
| GB2356197A (en) * | 1999-10-12 | 2001-05-16 | Merck & Co Inc | Amide derivatives as beta 3 agonists |
| WO2003024483A1 (fr) * | 2001-09-11 | 2003-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire |
| TWI295669B (en) * | 2002-10-30 | 2008-04-11 | Theravance Inc | Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds |
| US20040248979A1 (en) * | 2003-06-03 | 2004-12-09 | Dynogen Pharmaceuticals, Inc. | Method of treating lower urinary tract disorders |
| CA2580170A1 (en) * | 2004-10-18 | 2006-04-27 | Boehringer Ingelheim International Gmbh | Use of a beta-3 agonist for treating complaints of the prostate and the lower urogenital tract |
| AU2008233232A1 (en) * | 2007-03-29 | 2008-10-09 | Merck Sharp & Dohme Corp. | Combination therapy for the treatment-of lower urinary tract symptoms |
| PE20091825A1 (es) * | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
-
2010
- 2010-09-27 WO PCT/US2010/050328 patent/WO2011043942A1/en not_active Ceased
- 2010-09-27 US US13/500,574 patent/US20120202819A1/en not_active Abandoned
- 2010-09-27 JP JP2012533204A patent/JP5738871B2/ja active Active
- 2010-09-27 BR BR112012007829A patent/BR112012007829A2/pt not_active IP Right Cessation
- 2010-09-27 MX MX2012004134A patent/MX2012004134A/es not_active Application Discontinuation
- 2010-09-27 NZ NZ599233A patent/NZ599233A/xx not_active IP Right Cessation
- 2010-09-27 AU AU2010303811A patent/AU2010303811B2/en not_active Ceased
- 2010-09-27 CN CN2010800550891A patent/CN102638987A/zh active Pending
- 2010-09-27 CA CA2774992A patent/CA2774992A1/en not_active Abandoned
- 2010-09-27 EP EP10822429.6A patent/EP2485595A4/en not_active Withdrawn
- 2010-09-27 IN IN2782DEN2012 patent/IN2012DN02782A/en unknown
- 2010-09-27 RU RU2012118668/13A patent/RU2012118668A/ru not_active Application Discontinuation
- 2010-09-27 KR KR1020127008961A patent/KR20120093859A/ko not_active Withdrawn
-
2012
- 2012-03-20 IL IL218756A patent/IL218756A0/en unknown
- 2012-04-05 ZA ZA2012/02520A patent/ZA201202520B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102638987A (zh) | 2012-08-15 |
| KR20120093859A (ko) | 2012-08-23 |
| ZA201202520B (en) | 2012-12-27 |
| IL218756A0 (en) | 2012-06-28 |
| EP2485595A1 (en) | 2012-08-15 |
| CA2774992A1 (en) | 2011-04-14 |
| EP2485595A4 (en) | 2014-03-12 |
| IN2012DN02782A (https=) | 2015-09-18 |
| AU2010303811B2 (en) | 2013-01-24 |
| AU2010303811A1 (en) | 2012-04-19 |
| BR112012007829A2 (pt) | 2015-09-22 |
| JP2013507363A (ja) | 2013-03-04 |
| JP5738871B2 (ja) | 2015-06-24 |
| WO2011043942A1 (en) | 2011-04-14 |
| NZ599233A (en) | 2013-04-26 |
| RU2012118668A (ru) | 2013-11-20 |
| US20120202819A1 (en) | 2012-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012004134A (es) | Terapia de combinacion usando un agonista del receptor adrenergico beta 3 y un agente antimuscarinico. | |
| BR112012025017A2 (pt) | métodos para melhorar a qualidade do sono. | |
| MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
| WO2009129432A3 (en) | Alpha adrenergic receptor agonists for treatment of pain and/or inflammation | |
| MX2010004281A (es) | Composiciones y metodos para el tratamiento de la retinopatia diabetica. | |
| PH12013501341A1 (en) | Morphinan compounds | |
| MX2010005331A (es) | Composiciones y metodos para tratamiento de purpura. | |
| WO2009129494A3 (en) | Alpha and beta adrenergic receptor agonists for treatment of pain and/or inflammation | |
| MX2011011950A (es) | Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas. | |
| MX2010005642A (es) | Preparados, metodos y estuches para el tratamiento de la tos. | |
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| BRPI0822885A2 (pt) | Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral | |
| EP4275752A3 (en) | Treatment of addiction and impulse-control disorders using pde7 inhibitors | |
| PH12013500411A1 (en) | Treatment of myocardial infarction using tgf - beta antagonists | |
| PH12013500221A1 (en) | Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder | |
| EP2019646A4 (en) | METHOD, DEVICE AND SYSTEM FOR THE RELEASE OF A THERAPEUTIC ACTIVE IN THE EYE | |
| NZ597031A (en) | Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm) | |
| IN2012DN02423A (https=) | ||
| MX2013008729A (es) | Metodos y composiciones para tratar, reducir, o prevenir el deterioro del sistema visual de los animales. | |
| MX2013003638A (es) | Tratamiento en combinacion para rosacea. | |
| EP2490700A4 (en) | EXTERNAL SKIN CARE COMPOSITION COMPRISING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND USE THEREOF | |
| WO2009052073A3 (en) | Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists | |
| BRPI0916540B8 (pt) | inibidores do canal de ânion de superficíe de plasmódio como agentes antimaláricos | |
| MX2020002741A (es) | Uso de gaboxadol en el tratamiento de narcolepsia. | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: MERCK SHARP & DOHME CORP.* |
|
| HC | Change of company name or juridical status |
Owner name: MERCK SHARP & DOHME CORP.* |
|
| FA | Abandonment or withdrawal |